Welcome to our dedicated page for Alcon news (Ticker: ALC), a resource for investors and traders seeking the latest updates and insights on Alcon stock.
Alcon Inc. (ALC) generates frequent news as a global eye care company listed on the SIX Swiss Exchange and the New York Stock Exchange. Company communications emphasize a long heritage in eye care, a broad Surgical and Vision Care portfolio, and a large international patient reach, which together make Alcon a regular subject of healthcare, medical device and capital markets coverage.
News about Alcon often highlights developments in its Surgical and Vision Care segments, including product launches and portfolio updates that address conditions such as cataracts, glaucoma, retinal diseases and refractive errors. The company has stated that it is advancing global launches of major products across these franchises, and such initiatives are typically announced through press releases and investor events.
Investors following ALC news can also expect updates on corporate strategy and transactions. For example, Alcon has reported on a definitive merger agreement with STAAR Surgical Company and later announced the termination of that agreement in a January 6, 2026 press release. These items appear in both company news and related regulatory filings, providing insight into how Alcon approaches acquisitions and refractive surgery strategy.
Coverage may further include Alcon’s participation in major healthcare conferences, where senior executives present the company’s outlook and discuss its Surgical and Vision Care businesses. Such events are typically accompanied by webcasts and formal announcements. By monitoring this news feed, readers can track key developments affecting Alcon’s product portfolio, strategic direction and presence in the global eye care market.
Alcon (NYSE:ALC) announced significant efficiency improvements with their UNITY Vitreoretinal Cataract System (VCS) compared to existing systems. Two key studies demonstrated superior performance: The first study (n=179) showed 16% overall workflow efficiency gains in vitreoretinal surgery, with 33% faster console set-up and 38% quicker tear-down times versus CONSTELLATION Vision System.
The second study (n=303) revealed that UNITY VCS reduces cataract surgery turnover time by 6% and delivers 35% less total energy into the eye compared to CENTURION Vision System. These improvements are particularly significant given the projected 46.9% increase in AMD patients by 2040 and the global 12% decline in ophthalmologists.
Alcon (NYSE:ALC), the global eye care leader, showcased significant innovations at the 43rd ESCRS Congress in Copenhagen. The company introduced three major technologies now available in Europe: the UNITY Vitreoretinal Cataract System (VCS), Clareon Vivity intraocular lens (IOL), and Voyager DSLT for glaucoma treatment.
The company will present over 40 studies demonstrating the benefits of their technologies, including new data on Vivity IOLs showing positive outcomes in patients with special considerations. Key findings include reduced breakthrough pain medication use and less patient discomfort when performing cataract surgery at more physiologic IOP with CENTURION. Additionally, Alcon launched Intelligent Service Solutions (ISS) globally to maximize customer productivity through remote diagnostics and software updates.
Alcon (NYSE:ALC), the global leader in eye care, announced that CEO David Endicott will present at the 2025 Baird Global Healthcare Conference on September 9, 2025, at 9:05 a.m. ET. The presentation will be accessible via live webcast on the company's investor relations website.
Alcon serves over 260 million people in more than 140 countries annually through its Surgical and Vision Care products, focusing on conditions like cataracts, glaucoma, retinal diseases, and refractive errors. The company employs over 25,000 associates and maintains a 75-year heritage in eye care innovation.
Alcon (NYSE:ALC) reported Q2 2025 results with sales of $2.6 billion, up 4% on a reported basis and 3% in constant currency. The company posted diluted EPS of $0.35 and core diluted EPS of $0.76.
Key highlights include the successful US launch of Tryptyr, a first-in-class dry eye treatment, and the announced acquisition of STAAR Surgical to expand Alcon's myopia correction portfolio. The company generated $889 million in operating cash flow and returned $287 million to shareholders.
For 2025, Alcon updated its outlook, reducing net sales guidance to $10.3-10.4 billion (4-5% growth) and core operating margin to 19.5-20.5%, while maintaining core diluted EPS guidance of $3.05-3.15.
Alcon (NYSE:ALC), the global eye care leader, announced its participation in the 37th Asia-Pacific Association of Cataract and Refractive Surgeons (APACRS) Annual Meeting in Ahmedabad, India from August 21-23, 2025. The company will showcase four symposia, present 10 medical affairs scientific exchange presentations, and feature a hands-on experience zone.
Key highlights include new data on Vivity®, an Extended Depth of Focus (EDOF) intraocular lens, supported by over 10 clinical studies involving more than 700 patients. The company will also present research on cataract surgery performed at physiologic IOP in patients with diabetic retinopathy. Additionally, Alcon will officially introduce UNITY VCS (Vitreoretinal Cataract System) and UNITY CS (Cataract System), their next-generation Phaco/Vit platform, to the Indian market.
Alcon (SIX/NYSE: ALC) has entered into a definitive merger agreement to acquire STAAR Surgical (NASDAQ: STAA) for $28 per share in cash, representing a total equity value of approximately $1.5 billion. The deal offers a 59% premium to STAAR's 90-day VWAP.
The acquisition includes STAAR's EVO family of Implantable Collamer® Lenses (ICL), which provides vision correction for moderate to high myopia patients. This strategic move enhances Alcon's surgical vision correction portfolio, particularly targeting the growing myopia market, expected to affect 50% of the world's population by 2050.
The transaction is expected to close within 6-12 months, subject to regulatory and STAAR shareholder approval, and become earnings accretive in year two. Alcon plans to finance the acquisition through short- and long-term credit facilities.
Alcon (NYSE:ALC) has received Health Canada approval for its UNITY® Vitreoretinal Cataract System (VCS), marking the first innovation from its Unity portfolio. The breakthrough surgical technology combines vitreoretinal and cataract surgical capabilities in one integrated platform.
The system delivers significant improvements over Alcon's current CONSTELLATION® and CENTURION® systems, featuring up to 2x faster nucleus removal with 40% less energy, and the world's fastest vitrectomy probe at 30,000 cuts per minute. The platform includes a novel phacoemulsification modality and a first-of-its-kind phaco handpiece that estimates incision site temperature.
Following successful testing with over 200 surgeons from 30+ countries, Unity VCS is scheduled for commercial launch in early 2026.
Alcon (SIX/NYSE: ALC) announced its intention to acquire LumiThera, Inc. and its photobiomodulation (PBM) device for treating early and intermediate dry Age-Related Macular Degeneration (AMD). The PBM device, which received FDA authorization in November 2024 and CE Mark in November 2018, is the first technology demonstrating meaningful visual improvement in dry AMD patients over two years of treatment.
The pivotal LIGHTSITE III study showed significant results: 88% of patients maintained or gained vision, and 64% gained at least one line of visual acuity. The device is currently available in Europe, Latin America, Singapore, the UK, and the US. The acquisition, excluding LumiThera's diagnostic devices, is expected to close in Q3 2025, subject to customary conditions and shareholder approval.
Alcon (NYSE:ALC), the global eye care leader, has achieved certification as a Top Employer in Canada for 2025 by the Top Employers Institute. The recognition highlights Alcon Canada's excellence in key areas including People Strategy, Career Development, Rewards and Recognition, Purpose and Values, and Diversity & Inclusion.
The company's strengths include its comprehensive learning programs, leadership development initiatives, and commitment to sustainability, aiming for carbon neutrality by 2030. Alcon Canada's Head Office maintains ISO 14001:2015 Environmental Management System certification and demonstrates strong ethical business practices, including compliance with the Accessibility for Ontarians with Disabilities Act.
FAQ
What is the current stock price of Alcon (ALC)?
What is the market cap of Alcon (ALC)?
